Abstract
Mucous membrane pemphigoid (MMP) is a term categorizing a group of autoimmune sub-epithelial blistering diseases affecting primarily mucous membrane areas. These diseases mainly affect one or more mucous membranes, and can also affect the skin in a minor fashion. The common features that define this group of diseases are: (1). Mucous membranes are the predominantly affected areas; (2). Pathology of the lesional epithelium demonstrates a sub-epithelial blister; (3). Immunopathology of the peri-lesional epithelium shows linear deposition of immunoglobulin and/or complement component (C3) at the epithelial basement membrane. The therapeutic strategy should be based on both the progressiveness of the disease and the specific mucous membranes affected. Systemic treatments currently available for physicians to employ include dapsone, corticosteroids, immunosuppressives, intravenous immunoglobulin, and, most recently, biologics such as rituximab, an anti-CD20 monoclonal antibody to mature B cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid. Arch Dermatol. 2002;138(3):370–9.
Arafat SN, Suelves AM, Spurr-Michaud S, Chodosh J, Foster CS, Dohlman CH, et al. Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with Stevens-Johnson syndrome and ocular cicatricial pemphigoid. Ophthalmology. 2014;121(1):79–87.
Lavallee A, Bourret-Massicotte D, Laughrea PA. Childhood mucous membrane pemphigoid: a case with exclusively ocular involvement. Cornea. 2013;32(10):1399–401.
Shamim T, Varghese VI, Shameena PM, Sudha S. Pemphigus vulgaris in oral cavity: clinical analysis of 71 cases. Med Oral Patol Oral Cir Bucal. 2008;13(10):E622–4.
Mohan P, Srinivas CR, Leelakrishnan V. A rare initial presentation of esophageal involvement in pemphigus. Dis Esophagus. 2013;26(3):351.
Akhyani M, Chams-Davatchi C, Naraghi Z, Daneshpazhooh M, Toosi S, Asgari M, et al. Cervicovaginal involvement in pemphigus vulgaris: a clinical study of 77 cases. Br J Dermatol. 2008;158(3):478–82.
Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasis. N Engl J Med. 1990;323(25):1729–35.
Egan CA, Zone JJ. Linear IgA bullous dermatosis. Int J Dermatol. 1999;38(11):818–27.
Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammoan WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984;310(16):1007–13.
Diaz LA, Ratrie 3rd H, Saunders WS, Futamara S, Squiquera HL, Anhalt GJ, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990;86(4):1088–94.
Chan LS, Fine JD, Briggaman RA, Woodley DT, Hammerberg C, Drugge RJ, et al. Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol. 1993;101(3):262–7.
Shimanovich I, Hirako Y, Sitaru C, Hashimoto T, Brocker EB, Butt E, et al. The autoantigen of anti-p200 pemphigoid is an acidic noncollagenous N-linked glycoprotein of the cutaneous basement membrane. J Invest Dermatol. 2003;121(6):1402–8.
Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109(5):679–83.
Chen M, Chan LS, Cai X, O’Toole EA, Sample JC, Woodley DT. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol. 1997;108(1):68–72.
Zone JJ, Taylor TB, Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest. 1990;85(3):812–20.
Chan LS, Majmurdar AA, Tran HH, Meier F, Schumburg-Lever G, Chen M, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol. 1997;108(6):843–53.
Bernard P, Antonicelli F, Bedane C, Joly P, Le Roux-Villet C, Duvert-Lehembre S, et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol. 2013;149(5):533–40.
Rashid KA, Foster CS, Ahmed AR. Identification of epitopes within integrin b4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report. Invest Ophthalmol Vis Sci. 2013;54(12):7707–16.
Hayakawa T, Furumura M, Fukano H, Li X, Ishii N, Hamada T, et al. Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(4):483–96.
Taylor J, McMillan R, Shephard M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):161–71.
Günther C, Wozel G, Meurer M, Pfeiffer C. Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol. 2004;50(2):325–6.
Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol. 2004;29(6):674–6.
Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist. 2006;26(2):66–70.
Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol. 2011;91(5):604–5.
Carrozzo M, Arduino P, Bertolusso G, Cozzani E, Parodi A. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg. 2009;38(10):1071–6.
Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat. 2006;17(6):370–6.
Munyangango EM, Le Roux-Villet C, Doan S, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol. 2013;168(2):381–90.
Chaidemenos G, Sidiropoulos T, Katsioula P, Koussidou-Eremondi T. Colchicine in the management of mucous membrane pemphigoid. Dermatol Ther. 2011;24(4):443–5.
Staines K, Hampton PJ. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(1):e49–56.
Cafaro A, Broccoletti R, Arduino PG. Low-level laser therapy for oral mucous membrane pemphigoid. Lasers Med Sci. 2012;27(6):124.
Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457–61.
Kennedy JS, Devillez RL, Henning JS. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol. 2010;9(1):68–70.
Taverna JA, Lerner A, Bhawan J, Demierre M-F. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol. 2007;6(7):731–2.
Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol. 2009;89(1):101–2.
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843–9.
Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25(10):1238–40.
Wozniak K, Waszczykowska E, Hashimoto T, et al. Anti-epiligrin cicatricial pemphigoid initially limited to the upper respiratory tract. Br J Dermatol. 2006;154(4):779–81.
Segura S, Iranzo P, MartÃnez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol. 2007;56(6):960–7.
Gürcan HM, Ahmed AR. Intravenous immunoglobulin treatment in laryngeal pemphigoid. Clin Exp Dermatol. 2009;34(8):884–6.
Yu JT, Chong LY, Lee KC. A recalcitrant case of cicatricial pemphigoid. Hong Kong Med J. 2007;13(2):157–60.
Nishmura R, Fujimoto N, Kito K, Uchiyama K, Koga H, Hodohara K, et al. Refractory mucous membrane pemphigoid which developed after allogeneic stem cell transplantation and was successfully treated with rituximab. Eur J Dermatol. 2013;23(4):562–4.
Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68(3):499–506.
Czemik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012;45(1):111–8.
Suelves AM, Arcinue CA, Gonzalez-Martin JM, Kruh JN, Foster CS. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology. 2013;120(6):1201–9.
Nottage JM, Hammersmith KM, Murchison AP, Felipe AF, Penne R, Raber I. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea. 2013;32(6):810–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chan, L.S., Kwak, Y., Sami, N. (2016). Mucous Membrane Pemphigoid. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-26728-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26726-5
Online ISBN: 978-3-319-26728-9
eBook Packages: MedicineMedicine (R0)